Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School and by the Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and Development (WIHRD), University of Southampton.

  • Shepherd J, Rogers G, Anderson R et al. ICS and LABAs for the treatment of chronic asthma in adults and children aged 12 years and over: Systematic review and economic analysis, December 2006

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination:

I) Manufacturer/sponsors:

  • Altana Pharma Ltd

  • AstraZeneca UK Ltd

  • GlaxoSmithKline UK Ltd

  • IVAX Pharmaceuticals UK Ltd

  • Meda Pharmaceuticals Ltd

  • Ranbaxy UK Limited

  • Schering-Plough Ltd

  • Trinity-Chiesi Pharmaceuticals Ltd

II) Professional/specialist and patient/carer groups:

  • Action Against Allergy

  • Allergy UK

  • Asthma UK

  • British Lung Foundation

  • British Paediatric Respiratory Society

  • British Thoracic Society

  • Cochrane Airways Group

  • Department of Health

  • Education for Health

  • General Practice Airways Group

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Physicians

  • Royal College of Physicians of Edinburgh

  • Welsh Assembly Government

III) Commentator organisations (without the right of appeal):

  • Asthma and Allergy Research Group, University

  • AstraZeneca UK Ltd

  • British National Formulary

  • GlaxoSmithKline UK Ltd

  • IVAX Pharmaceuticals UK Ltd

  • Meda Pharmaceuticals Ltd

  • Medicines and Healthcare products Regulatory Agency

  • Merck Pharmaceuticals Ltd

  • Napp Pharmaceuticals Ltd

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • Peninsula Technology Assessment Group

  • Ranbaxy UK Limited

  • Respiratory Research Group, University of Glasgow

  • Southampton Health Technology Assessment Centre, University of Southampton

  • TEVA UK Ltd

  • Trinity-Chiesi Pharmaceuticals Ltd

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on inhaled corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD:

  • Professor Neil Barnes, Consultant Respiratory Physician nominated by British Thoracic Society – clinical specialist

  • Dr Jonathan Grigg, Professor of Paediatric and Respiratory Medicine nominated by Royal College of Paediatrics and Child Health – clinical specialist

  • Mrs Jennifer Versnel, Executive Director, Research & Policy nominated by Asthma UK – patient expert

  • Dr Mike Thomas, External Affairs Liaison nominated by General Practice Airways Group – clinical specialist